Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders - PubMed (original) (raw)

Review

. 2002 Autumn;36(4):35-83.

Affiliations

• PMID: 12858143

Review

Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders

Carlos A Zarate et al. Psychopharmacol Bull. 2002 Autumn.

Abstract

ine levels may be of limited benefit. This article reviews the growing body of data suggesting that agents which modulate the glutamatergic system may have utility in the long-term treatment of severe, recurrent mood disorders. Such strategies may serve to enhance and maintain normal synaptic connectivity, thereby allowing the chemical signal to reinstate the optimal functioning of critical circuits necessary for normal affective functioning. There are a number of glutamatergic plasticity enhancing" strategies which may be of considerable utility in the treatment of mood disorders. Among the most immediate ones are N-methyl-D-aspartate antagonists, glutamate release-reducing agents, and a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid potentiators. This research progress holds much promise for the development of novel therapeutics for the treatment of severe, refractory mood disorders.

PubMed Disclaimer

Similar articles

• Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression.
  Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, A Gray N, Zarate CA Jr, Charney DS. Manji HK, et al. Biol Psychiatry. 2003 Apr 15;53(8):707-42. doi: 10.1016/s0006-3223(03)00117-3. Biol Psychiatry. 2003. PMID: 12706957 Review.
• Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder.
  Zarate CA Jr, Singh J, Manji HK. Zarate CA Jr, et al. Biol Psychiatry. 2006 Jun 1;59(11):1006-20. doi: 10.1016/j.biopsych.2005.10.021. Epub 2006 Feb 17. Biol Psychiatry. 2006. PMID: 16487491 Review.
• Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system.
  Zarate CA Jr, Du J, Quiroz J, Gray NA, Denicoff KD, Singh J, Charney DS, Manji HK. Zarate CA Jr, et al. Ann N Y Acad Sci. 2003 Nov;1003:273-91. doi: 10.1196/annals.1300.017. Ann N Y Acad Sci. 2003. PMID: 14684452 Review.
• Emerging Novel Treatments for Severe Mood Disorders Involving Cellular Plasticity Cascades.
  Machado-Vieira R, Zarate CA Jr, Manji HK. Machado-Vieira R, et al. Curr Psychos Ther Rep. 2006 Dec;4(4):181-190. doi: 10.1007/BF02629394. Curr Psychos Ther Rep. 2006. PMID: 25620894 Free PMC article.
• Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.
  Machado-Vieira R, Salvadore G, Ibrahim LA, Diaz-Granados N, Zarate CA Jr. Machado-Vieira R, et al. Curr Pharm Des. 2009;15(14):1595-611. doi: 10.2174/138161209788168010. Curr Pharm Des. 2009. PMID: 19442176 Free PMC article. Review.

Cited by

• rs1344706 polymorphism of zinc finger protein 804a (ZNF804a) gene related to the integrity of white matter fiber bundle in schizophrenics.
  Zhou J, Bao Q, Liang S, Guo H, Meng X, Zhang G, Li P. Zhou J, et al. Exp Ther Med. 2021 Jul;22(1):778. doi: 10.3892/etm.2021.10210. Epub 2021 May 18. Exp Ther Med. 2021. PMID: 34055077 Free PMC article.
• Ketamine and the next generation of antidepressants with a rapid onset of action.
  Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CA Jr. Machado-Vieira R, et al. Pharmacol Ther. 2009 Aug;123(2):143-50. doi: 10.1016/j.pharmthera.2009.02.010. Epub 2009 May 3. Pharmacol Ther. 2009. PMID: 19397926 Free PMC article. Review.
• A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder.
  Milak MS, Proper CJ, Mulhern ST, Parter AL, Kegeles LS, Ogden RT, Mao X, Rodriguez CI, Oquendo MA, Suckow RF, Cooper TB, Keilp JG, Shungu DC, Mann JJ. Milak MS, et al. Mol Psychiatry. 2016 Mar;21(3):320-7. doi: 10.1038/mp.2015.83. Epub 2015 Aug 18. Mol Psychiatry. 2016. PMID: 26283639 Free PMC article.
• Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.
  Sanacora G, Zarate CA, Krystal JH, Manji HK. Sanacora G, et al. Nat Rev Drug Discov. 2008 May;7(5):426-37. doi: 10.1038/nrd2462. Nat Rev Drug Discov. 2008. PMID: 18425072 Free PMC article. Review.
• Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments.
  Machado-Vieira R, Zarate CA Jr. Machado-Vieira R, et al. Depress Anxiety. 2011 Apr;28(4):267-81. doi: 10.1002/da.20800. Epub 2011 Feb 24. Depress Anxiety. 2011. PMID: 21456037 Free PMC article. Review.

Publication types

MeSH terms

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information